Hepatitis C treatments are an integral part of the biotech’s product line. Recent approval for a competitor’s comprehensive Hep C drug adds new pressure.
Looking for leads, investment insights, or competitive intelligence?
News about Gilead Sciences
The PrEP drug will be publicly funded in New Zealand for those at high risk for HIV infection.
Juno's stock is up a staggering 76% since rumors of the Celgene deal emerged last week.
The FDA approved 46 novel drugs in 2017 versus 22 in 2016.
The FDA approved Spark Therapeutics' Luxturna on Tuesday.